Day One to Present at the 44th Annual J.P. Morgan Healthcare Conference
Day One Biopharmaceuticals (Nasdaq: DAWN) announced that CEO Dr. Jeremy Bender will present at the 44th Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Day One Biopharmaceuticals (Nasdaq: DAWN) announced that CEO Dr. Jeremy Bender will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12 at 5:15 p.m. PT / 8:15 p.m. ET. A live audio webcast will be available via the company’s News & Events web page and an archived replay will be accessible for 30 days after the live presentation.
Details
News Market Reaction – DAWN
On Dec 16, the day this news came out, DAWN closed 0.24% below the previous close.
Data tracked by StockTitan Argus for the Dec 16 session.
Key Figures
- Conference edition
- 44th Annual
- J.P. Morgan Healthcare Conference
- Presentation date
- January 12
- Conference presentation schedule
- Presentation time PT
- 5:15 p.m. PT
- Scheduled J.P. Morgan presentation
- Presentation time ET
- 8:15 p.m. ET
- Scheduled J.P. Morgan presentation
- Webcast replay duration
- 30 days
- Archived replay availability
Historical Context
-
Three-year FIREFLY-1 OJEMDA data with efficacy and durability metrics.
-
Announcement of fireside chat at Piper Sandler healthcare conference.
-
Agreement to acquire Mersana Therapeutics via cash plus CVR structure.
-
Planned oral presentation of long‑term OJEMDA data at SNO meeting.
-
Q3 2025 results with higher OJEMDA revenue and raised 2025 guidance.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BRISBANE, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that Dr. Jeremy Bender, chief executive officer, will present during the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12 at 5:15 p.m. Pacific Time / 8:15 p.m. Eastern Time.
A live audio webcast of the presentation will be available by visiting the News & Events section of the Company’s website at www.dayonebio.com. An archived replay of the webcast will be available for 30 days following the live presentation.
About Day One Biopharmaceuticals
Day One Biopharmaceuticals is a commercial-stage biopharmaceutical company that believes when it comes to pediatric cancer, we can do better. The Company was founded to address a critical unmet need: the dire lack of therapeutic development in pediatric cancer. Inspired by “The Day One Talk” that physicians have with patients and their families about an initial cancer diagnosis and treatment plan, Day One aims to re-envision cancer drug development and redefine what’s possible for all people living with cancer—regardless of age—starting from Day One.
Day One partners with leading clinical oncologists, families, and scientists to identify, acquire, and develop important targeted cancer treatments. The Company’s pipeline includes tovorafenib (OJEMDA™) and DAY301.
Day One is based in Brisbane, California. For more information, please visit www.dayonebio.com or find the Company on LinkedIn or X.
Day One uses its Investor Relations website (ir.dayonebio.com), its X handle (x.com/DayOneBio), and LinkedIn Home Page (linkedin.com/company/dayonebio) as a means of disseminating or providing notification of, among other things, news or announcements regarding its business or financial performance, investor events, press releases, and earnings releases, and as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.
DAY ONE MEDIA
media@dayonebio.com
DAY ONE INVESTORS
LifeSci Advisors, PJ Kelleher
pkelleher@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.